IC is typically characterized by daily full-force crying for a minimum of 3 hrs, on a minimum of 3 days per week, for at least 3 weeks (Gordon et al., 2018). It is reported about one in four infants younger than three months develop colic (Indrio et al., 2023). Although IC often resolves by three months of age, it remains to be stressful for parents and may even cause maternal postpartum depressive symptoms (Mercuri et al., 2023). Considerable research indicates that the intestinal microbiome’s composition is related to infant colic symptoms, even though the pathophysiology of this digestive condition is still inadequately comprehended (Korpela et al., 2020). Firstly, it has been hypothesized that the developing GI microbiome and the occurrence of excessive crying in infants between the ages of two weeks and three months-the normal time frame during which the gut is typically colonized by bacteria are related (Zeevenhooven et al., 2018). Additionally, the gut microbiota interacts with the gut-brain axis through multiple signaling pathways, including neural, endocrine, immune, and humoral signaling pathways (Deng et al., 2021). Given this, it may influence central and gut neural functions, such as pain perception in infants via the gut-brain axis, which may be associated with excessive crying (Socala et al., 2021). In the past decades, numerous studies illustrated that the GI microbial profiles of infants with colic differ from those without colic in microbial diversity, stability, and community composition (de Weerth et al., 2013; Savino et al., 2017). Moreover, the results showed colicky infants were less frequently colonized by Lactobacillus, Bifidobacterium and more frequently enriched with the gas-forming Coliforms (mostly Escherichia, Klebsiella) or other species (Savino et al., 2009; de Weerth et al., 2013; Savino et al., 2017; Sommermeyer et al., 2022; Kozhakhmetov et al., 2023).

We concluded that L. reuteri may be useful in the improvement of breastfeeding babies with IC based on six randomized controlled trials (RCTs), shown in Table 1 . Accordingly, administering 1×10⁸ colony-forming units (CFU) of L. reuteri DSM 17938 per day for 21 to 30 days can significantly decrease daily crying and fussing times, and reduce the duration of crying episodes in colicky breast-fed infants, consistent with remission of maternal depression (Savino et al., 2010; Szajewska et al., 2013; Chau et al., 2015; Mi et al., 2015; Savino et al., 2018a; Savino et al., 2018b). Similar results were reported when analyzing the probiotic potential of L. reuteri ATCC 55730 in colicky infants, the superiority was still maintained compared with simethicone intervention (Savino et al., 2007). However, whether L. reuteri is useful in the treatment of formula-fed colicky infants is still controversial. Data shown in the other two RCT studies demonstrated that L. reuteri did not help manage the symptoms of colicky infants (Sung et al., 2014; Turco et al., 2021). One study showed that a partially hydrolyzed formula added with maltodextrins and L. reuteri DSM 17938 showed no preference for the standard formula on colicky symptoms, but the unsatisfactory results may attribute to the addition of maltodextrins in the probiotics group (Turco et al., 2021). In another study included breastfed and formula-fed colicky newborns, researchers found that L. reuteri DSM 17938 had no beneficial impact on crying or fusing time, instead, more fussing occurred in formula-fed infants following probiotic treatment (Sung et al., 2014). The conflict results may be explained by the differences in gut microbiota, whose composition in early infancy seemed to be influenced by various factors, including the delivery mode, infant feeding pattern, gestational age, and the history of antibiotic use (Kapourchali and Cresci, 2020). Formula-fed babies exhibited an increased gut bacterial community richness relative to breast-fed babies, with a greater abundance of Clostridium difficile (Azad et al., 2013). Following the administration of L. reuteri DSM 17938, breast-fed colicky infants showed a substantial rise in fecal Lactobacilli and a drop in fecal Escherichia (E.) coli (Savino et al., 2010; Savino et al., 2018b). From these findings, the therapeutic effectiveness of L. reuteri could be influenced by the microbiome composition of the infant’s GI tract, which would account for the differences between the effect on crying duration in breast-fed and formula-fed infants.

It is also reported that colicky infants showed increased serum concentrations of inflammatory interleukin (IL)-8, monocyte chemoattractant protein-1, and higher fecal calprotectin levels, indicating the existence of systemic and intestinal local inflammation (Partty et al., 2017). L. reuteri DSM 17938 treatment can increase circulating FoxP3 concentration and reduce fecal calprotectin, indicating the underlying mechanisms of L. reuteri to improve colic may be linked to the property of alleviating inflammation (Savino et al., 2018a; Savino et al., 2018b). According to a recent secondary analysis research based on a large observational study, L. reuteri-containing formula was superior to standard formula without probiotics in preventing infant colic, similar to breast feeding (Happy Tummy et al., 2023). Furthermore, the probiotic potential of L. reuteri DSM 17938 given at a dosage of 1×10⁸ CFU per day for 90 days to prevent IC is demonstrated by two RCT studies in newborns (Indrio et al., 2014; Savino et al., 2015). This statement was also supported by one prospective cohort study, which showed maternal consumption with L. reuteri DSM 26866 in the latter four weeks of gestation was able to protect infants from colic (Pourmirzaiee et al., 2020). In conclusion, since L. reuteri may ameliorate colic symptoms mainly by altering the microbial colonization pattern in colicky infants, it is a receptive therapy for colicky infants without side effects and recommendable supplements for newborns to prevent IC.

Recent data has shown that acute diarrheal disease leads to 179 million outpatient visits every year in the United States, associated with various pathogen infections such as Shigella, E. coli, rotavirus, norovirus and antibiotic use (Meisenheimer Es Md et al., 2022). Diarrhea is also identified as the leading infectious cause of childhood morbidity and mortality (Ahmed et al., 2021). Previously several specific probiotic strains have demonstrated antidiarrheal effects (Skrzydlo-Radomanska et al., 2020; Lukasik et al., 2022). An increasing number of studies have been conducted to clarify the function of L. reuteri in diarrhea since Shornikova and his colleagues first analyzed the effectiveness of L. reuteri DSM 17938 in pediatric acute watery diarrhea and demonstrated that it can dosage-dependently shorten the duration of acute watery diarrhea (Shornikova et al., 1997a; Shornikova et al., 1997b). Previous nine RCTs, which demonstrated that L. reuteri DSM 17938 was capable of reducing the frequency, length of time, and incidence of diarrhea in children and adults, especially in those with lower nutritional status, supported the drug’s potential benefits in treating and preventing diarrheal diseases (Agustina et al., 2012; Francavilla et al., 2012; Jones et al., 2013; Dinleyici et al., 2014; Gutierrez-Castrellon et al., 2014; Dinleyici et al., 2015; Pernica et al., 2017; Maragkoudaki et al., 2018; Kambale et al., 2023). Additionally, L. reuteri DSM 17938 could shorten a child’s stay in the hospital due to acute gastroenteritis or infectious diarrhea (Dinleyici et al., 2014; Szymanski and Szajewska, 2019). However, in the situation of nosocomial diarrhea, three RCTs produced contrary findings (Wanke and Szajewska, 2012; Urbanska et al., 2016; Kolodziej and Szajewska, 2019). The investigators found that L. reuteri DSM 17938 was ineffective in preventing diarrhea in inpatient children received antibiotics, regardless of the given dosage (1×10⁸ CFU once daily, or 2×10⁸ CFU twice daily, or 2×10⁹ CFU once daily while in hospital) (Wanke and Szajewska, 2012; Urbanska et al., 2016; Kolodziej and Szajewska, 2019). While L. reuteri ATCC 55730 was reported to be able to prevent antibiotic-associated diarrhea in hospitalized adults in another study (Cimperman et al., 2011). Different from the prior studies, this clinical trial analyzed adult patients who were mainly treated with combined antibiotic therapy, and the subjects were given L. reuteri ATCC 55730 1×10⁸ CFU twice daily for 28 days (Cimperman et al., 2011). Given these limited data, the function of L. reuteri in preventing antibiotic-associated diarrhea is ambiguous, which may be strain-specific and depend on the gut microbiota community disrupted by antibiotics. Of note, none of the mentioned clinical studies analyzed the fecal L. reuteri abundance before or after L. reuteri administration. All these RCT studies are depicted in Table 2 .

Enterotoxigenic E. coli is a main pathogen of infectious diarrhea in childhood and postweaning piglets (Kotloff, 2022; Qin et al., 2023b). Gut microbiota disruption observed in diarrheal piglets was described as a reduction of Lactobacillus, enriched abundance of E. coli, and increased lipopolysaccharide (LPS) biosynthesis (Li et al., 2023b). Supplement of L. reuteri can reverse the enriched Pseudomonadota and the depleted Bacteroidota triggered by E. coli infection and reduce jejunum E. coli content, thus preserving intestinal disruption (Wang et al., 2018; Lu et al., 2023). L. reuteri stains including L. reuteri HCM2 and L. reuteri PSC102 have been reported to suppress the growth of E. coli in vitro and inhibit its adherence to intestinal epithelial cells (Wang et al., 2018; Ali et al., 2023). Moreover, L. reuteri was also reported to possess the ability to upregulate the expression of tight junction (TJ) proteins and E-cadherin, thereby maintaining intestinal permeability in infected mice (Karimi et al., 2018; Lu et al., 2023). In a rotavirus-infected murine model, L. reuteri can reduce diarrhea duration and alleviate inflammation, probably associated with accelerated intestinal epithelium turnover and restored gut microbiome diversity (Preidis et al., 2012). Particularly, the efficiency of L. reuteri to increase enterocyte proliferation and migration seemed to be influenced by host nutritional status (Preidis et al., 2012). Except these, the therapeutic application of L. reuteri in infectious diarrhea may also be related to its metabolite production such as reuterin, with the ability to inhibit an extensive range of germs (Collinson et al., 2020).

These results illustrated that the therapeutic efficiency of L. reuteri in diarrhea may depend on regulation of gut microbiota and barrier, which is strain-specific and reliant on age, pathogen, nutritional status, and the disease situation as well. To sum up, L. reuteri can be recommended as an adjuvant to rehydration treatment for diarrhea in therapeutic settings, but its function in prophylactic settings still requires more research, especially in the antibiotics-use setting.

Constipation is an intestinal condition that could affect individuals of all ages and dramatically lower their quality of life (Saviano et al., 2021). With a prevalence spanning from 7% to 30%, constipation is also one of the most prevalent pediatric disorders (Wegner et al., 2018). The fundamental mechanism of constipation, which typically has a functional cause without an organic origin, is largely unknown (Mulhem et al., 2022). It is suggested that disruption of the intestinal flora play a role in functional constipation (FC) (Zhang et al., 2021). The results may be conflict reliant on measurements. Based on traditional microbiological culture tests, enriched Bifidobacteria and Lactobacillus were observed in children with FC, while decreased abundance of Bifidobacterium and Lactobacillus was seen in adult FC patients (Zoppi et al., 1998; Khalif et al., 2005). Nowadays though gene sequencing analysis, it seems consistent that Firmicutes relative abundance is increased while Bacteroidetes frequency is heterogeneous based on population, and the gut microbe pattern differs in different subtypes of constipation as well (Zhu et al., 2014; Mancabelli et al., 2017; Yu et al., 2023a).

A couple of RCTs have evaluated the effectiveness of L. reuteri DSM 17938 in treating FC, depicted in Table 2 . The investigations demonstrated that L. reuteri DSM 17938 single-drug administration significantly alleviated constipation both in children and adults, involving improvement in defecation frequency, painful defecation, and reduced fecal mass in the rectum (Coccorullo et al., 2010; Ojetti et al., 2014; Riezzo et al., 2018; Garcia Contreras et al., 2020; Kubota et al., 2020). However, L. reuteri DSM 17938 did not show additional improvement in FC when regarded as adjuvant therapy for lactulose or macrogol (Jadresin et al., 2018; Wegner et al., 2018; Kubota et al., 2020). Only one study investigated the gut microbiome community alternations, in which the limited data revealed that L. reuteri treatment did not alter the gut microbiota composition of the pediatric subjects with FC (Kubota et al., 2020).

To note, current evidence showed that L. reuteri DSM 17938 improved bowel movements, but did not affect stool consistency (Coccorullo et al., 2010; Kubota et al., 2020). The defecation frequency was found to be negatively correlated with genus Oscillospira, Megasphaera, and Ruminococcus (Kubota et al., 2020). On one hand, L. reuteri DSM 17938 can improve intestinal motility and promote intestinal transit, partially via controlling some GI peptide pathways. According to research by Riezzo and colleagues, the therapeutic efficacy of L. reuteri DSM 17938 in FC may be associated with serum brain-derived neurotrophic factor and serotonin (5-HT) concentrations (Riezzo et al., 2019). Tryptophan metabolism may be impacted by L. reuteri, which would reduce the level of 5-HT in circulation (Montgomery et al., 2022). The connection between the intestinal flora and the enteric neural systems involves the 5-HT pathways, which have advantages for irritating the local enteric nerve responses and promoting motility (Ge et al., 2017; Agus et al., 2018). On the other hand, L. reuteri DSM 17938 is capable of producing short-chain fatty acids (SCFAs), the substances involved in boosting intestinal peristalsis and colonic myoelectric cell response, all of which are effective for treating chronic FC (Wu et al., 2013; Hurst et al., 2014; Calvigioni et al., 2023).

However, there is still no sufficient data in the field of L. reuteri application for constipation prevention. A prospective RCT study carried out by Indrio and colleagues revealed that oral supplementation with L. reuteri DSM 1793 in newborns effectively prevented constipation within the first 3 months after birth (Indrio et al., 2014). In conclusion, present findings indicate that L. reuteri can be recommended to be used in the management of FC as an alternative therapy for traditional drugs.

FAP, which is the most prevalent type of abdominal pain in children and teenagers, with a prevalence of about 14 percent, is described as chronic or recurring pain without an organic cause (Bao et al., 2023). Although most FAP is often self-managed, it can have adverse effects on life quality, suffered children’s after-school activities, and school attendance, and may interfere with regular family life (Thapar et al., 2020). The disease was currently considered a disorder of the “brain-gut axis”, and gut microbiome changes could be engaged in its pathogenesis, but the available data is insufficient to draw a conclusion (Zhou et al., 2022a). Given the limitations of medication in children, probiotics arise as a possibly pleasant therapeutic approach for the treatment of pediatric FAP (Trivic et al., 2021). Six RCT investigations on L. reuteri DSM 17938’s medicinal potential are summarized in Table 3 . The studies demonstrated that administration of L. reuteri DSM 17938 for 4 to 12 weeks reduced the pain intensity, the frequency of episodes, and increased days without pain in irritable bowel syndrome or FAP-affected children without adverse events (Romano et al., 2014; Eftekhari et al., 2015; Weizman et al., 2016; Jadresin et al., 2017; Maragkoudaki et al., 2017; Jadresin et al., 2020). However, one study proposed that L. reuteri DSM 17938 was equally effective in relieving pain in both the placebo and L. reuteri groups of children with FAP (Eftekhari et al., 2015). The authors speculated that the result may be explained by psychological effects since L. reuteri DSM 17938 showed no superiority to placebo (Eftekhari et al., 2015). None of the studies explored gut flora profiles after L. reuteri treatment, so we cannot draw a conclusion about the precise mechanism of L. reuteri application in pediatric FAP.

By enhancing opioid receptor activity in the afflicted tissues, Hegde and his colleagues reported that the dorsal root ganglia neurons projecting to the dilated colon exhibited attenuated hyperexcitability after L. reuteri recolonization, thus preventing visceral hypersensitivity in lumen distension in rats (Hegde et al., 2020). Additionally, L. reuteri may exhibit the ability to reduce gut pain by reducing signaling from the pain receptor transient receptor potential vanilloid 1 channel in the intestine (Pang et al., 2022). Collectively, although L. reuteri could be an attractive choice in treating FAP-related diseases due to its safety feature, there is currently no powerful proof to recommend L. reuteri application in FAP and further long-run researches are still needed to explore the definite mechanism.

Helicobacter pylori (H. pylori) is the key pathogen of chronic active gastritis, peptic and duodenal ulcers, with the global prevalence of infection exceeding 50%, also considered a high-risk factor for gastric cancer (de Brito et al., 2019). Currently, the effectiveness of treatment has been greatly impaired by the fast global emergence of antibiotic resistance to H. pylori, and the quadruple approach for H. pylori elimination could further exacerbate GI disease (Chen et al., 2021). It is suggested that eradication of H. pylori may lead to disruption of gut microbiota, featured by reduced Actinobacteria as well as Bacteroidetes abundances and enriched Proteobacteria (Sitkin et al., 2022). Specific probiotics may be helpful in reducing side effects triggered by first-line antimicrobial therapy and enhancing the efficacy of H. pylori eradication therapy (Liang et al., 2022). In previous RCT studies, L. reuteri was shown to reduce H. pylori load but seemed to be unable to increase eradication rates of H. pylori as an adjuvant for first-line therapy (Imase et al., 2007; Francavilla et al., 2008; Mehling and Busjahn, 2013; Francavilla et al., 2014; Holz et al., 2015; Dore et al., 2019; Poonyam et al., 2019; Yang et al., 2021; Dore et al., 2022; Moreno Marquez et al., 2022; Naghibzadeh et al., 2022), shown in Table 4 . Notably, several studies showed that L. reuteri can reduce abdominal pain, distension, and other eradication treatment-related adverse events, consistent with decreased GI symptom rating scale scores in H. pylori-positive subjects, thus governing patient compliance (Lionetti et al., 2006; Francavilla et al., 2008; Francavilla et al., 2014; Poonyam et al., 2019; Yang et al., 2021; Moreno Marquez et al., 2022). Two studies analyzed the alternations of the gut flora after combined therapy of this probiotics and eradication treatment, which revealed that L. reuteri can change the gut microbiota composition in H. pylori-positive patients but cannot fully counteract gut dysbiosis induced by antibiotics (Yang et al., 2021; Dore et al., 2022). It means that the benefits brought by L. reuteri supplement cannot be attributed to restored gut microbiota balance. Particularly, L. reuteri can survive the gastric acid environment and colonize the gastric mucosa (Dargenio et al., 2021). It is reported that L. reuteri can inhibit the early colonization stages of H. pylori in the human GI tract, associated with the suppression of the binding of H. pylori to putative glycolipid receptor molecules (Holz et al., 2015). Besides, L. reuteri produces reuterin, an antibiotic that targets H. pylori, thus reducing H. pylori load (Urrutia-Baca et al., 2018). Meanwhile, a most recent survey also revealed that L. reuteri 2892 attenuated H. pylori-induced gastritis by its anti-inflammatory and anti-oxidative stress characteristics as well as suppressing the gene expression of the virulence factor CagA (Forooghi Nia et al., 2023). Recent studies also focus on the relationship between L. reuteri and cancer diseases, it has been demonstrated that L. reuteri exerts an anti-tumor effect in gastric cancer MKN1 cells, but data is still limited about L. reuteri application in gastric cancers related to H. pylori infection (Kim et al., 2022a).

Overall, L. reuteri has shown superiority as a salvageable treatment for side effects brought by eradication therapy, yet we still need further studies to delve deeper into the research gap between L. reuteri application and H. pylori-associated cancer.

Crohn’s disease and ulcerative colitis are categorized as chronic IBD, which have evolved into a worldwide burden with increasing incidence (Nishikawa et al., 2021). It is reported that about one in five children needing a colectomy during childhood while the intestinal damage and complications brought by Crohn’s disease are still a difficulty for disease management (Cheng et al., 2021; Gordon et al., 2022). Multiple factors, such as the interaction between genetic background and environment, especially including a potential association between impaired gut microbial homeostasis and inflammation, and gut barrier disruption as well, have been suggested to be engaged in IBD pathogenesis (Larabi et al., 2020). It was observed in IBD subjects that the relative abundance of Proteobacteria, especially E. coli, was increased while the content of Bacteroidetes and Firmicutes was depleted, along with the reduced gut microbiota diversity (Nishino et al., 2018; Vester-Andersen et al., 2019). It has been revealed in a previous clinical trial, whereby, rectal infusion of L. reuteri ATCC 55730 effectively improved inflamed mucous membranes and reduced mucosal expression levels of inflammatory markers in active distal ulcerative colitis in children (Oliva et al., 2012), shown in Table 5 .

According to Liu and his colleagues, peroral treatment with L. reuteri ATCC PTA 4659 improved colitis severity clinically and morphologically in mouse colitis caused by dextran sulfate sodium (Liu et al., 2022a). Other studies investigated the efficiency of L. reuteri R2LC, ATCC PTA 4659, F-9-35, and 5454, these strains also can alleviate inflammation in mice colitis, characterized by downregulated pro-inflammatory tumor necrosis factor-α (TNF-α), IL-1β, and interferon-γ, the decisive cytokines in colitis development (Ahl et al., 2016; Sun et al., 2018; Hrdy et al., 2020). This may be explained by the boosted expression of the TJ proteins along with cytoprotective heat shock proteins after L. reuteri therapy, thereby conferring protection against defects in gut barrier function (Ahl et al., 2016; Liu et al., 2022a). Meanwhile, L. reuteri supplement can also reverse gut microbiota dysbiosis induced by colitis. It was reported that after L. reuteri FYNDL13 treatment, enriched beneficial bacteria (Bifidobacterium, Akkermansia, Blautia and Oscillospira) together with reduced harmful bacteria (Bacteroides and Sutterella) content was observed (Lin et al., 2023). Moreover, L. reuteri therapy can offset bacterial translocation to the mesenteric lymph nodes caused by colitis, leading to the amelioration of excessive immune reactions (Liu et al., 2022a). Secretory immunoglobulin (Ig) A is responsible for bacterial translocation and bacterial toxins neutralization in the intestinal mucosa (Tezuka and Ohteki, 2019). Recently, it was discovered that orally administered L. reuteri R2LC stimulated the proliferation of the B lymphocytes in Peyer’s patches and induced IgA production and secretion to the intestinal lumen via the PD-1 pathway (Liu et al., 2021a). Consequently, treatment based on L. reuteri R2LC regulated alterations in the gut microbiome and shielded against colitis caused by dextran-sulfate-sodium (Liu et al., 2021a). Dendritic cells (DCs) are responsible for handling pathogens when the gut barriers are disrupted in IBD (Wei et al., 2022). L. reuteri was proven to possess the potential to promote DCs differentiation and maturation and boost regulatory T cells (Tregs) induction (Haileselassie et al., 2016; Hrdy et al., 2020). In addition, it is demonstrated that L. reuteri may reduce intestine inflammation by the mechanisms dependent on aryl hydrocarbon receptor activation, an immune and bacteria sensor receptor, correlated to inflammatory responses in IBD pathogenesis (Pernomian et al., 2020). The tryptophan metabolites from L. reuteri can activate aryl hydrocarbon receptors, inducing IL-22 production to maintain mucosal protection (Zelante et al., 2013). And the microbial histamine produced by L. reuteri has been proven to ameliorate intestinal inflammation in mice via activating H2R signaling (Gao et al., 2015). It was also reported that LPxTG-motif surface protein derived from L. reuteri SH 23 can alleviate inflammation in a mice colitis model via the inhibition of the MAPK-dependent NF-κB transduction way (Zong et al., 2023).

Colon mucosa and submucosa may inflame and herniate through the muscular layer in cases of diverticulitis (Barbaro et al., 2022). Diet and lifestyle factors may induce changes in the gut microbiota community that contributes to mucosal inflammation and diverticulitis (Piccioni et al., 2021). Probiotics could be beneficial in diverticular disease because they can prevent harmful bacteria from adhering to the intestinal mucosa and from producing inflammatory markers (Piccioni et al., 2021). Two previous RCTs examined L. reuteri’s function in managing acute uncomplicated diverticulitis (AUD) in light of recent recommendations that the condition be treated without the use of antibiotics (Petruzziello et al., 2019; Ojetti et al., 2022). They revealed that the treatment with L. reuteri ATCC PTA 4659 can alleviate abdominal pain and reduce inflammatory markers as well as the duration of hospitalization in patients with AUD (Petruzziello et al., 2019; Ojetti et al., 2022), shown in Table 5 .

Therefore, the above preclinical studies validate the therapeutic potential of specific strains of L. reuteri to enhance the natural defense of gut epitheliums, alleviate hyperimmune response and restore gut microecology balance in inflammatory intestinal diseases. Although clinical data are limited, L. reuteri can be an attractive adjuvant therapy for IBD and diverticulitis.

As per global statistics, CRC is ranked third as the most prevalent type of malignancy and the fourth major contributor to deaths related to cancer worldwide (Baidoun et al., 2021). As is known to all, IBD is linked to the onset and progression of CRC (Mathey et al., 2021). Dysplasia, clonal proliferation, and malignant progression might all be caused by gut dysbacteriosis, which may also have dramatic effects on genetics and epigenetics (Eslami et al., 2019). Previously, researchers identified gut flora dysbiosis in patients with CRC, including the depletion of L. gallinarum, Streptococcus thermophilus and enriched Firmicutes and Bacteroidetes, along with decreased bacterial diversity (Dai et al., 2018). Reduced abundance of Lactobacillus, Roseburia and Bifidobacterium in gut microbiota composition was observed in early precursors of CRC including adenoma and serrated polyp (Rezasoltani et al., 2018).

Although the prognosis of CRC patients without local or distant metastatic disease is generally favorable, there are currently inadequate viable therapies for individuals with metastatic cancer (Bell et al., 2022). Accordingly, probiotic therapy has recently gained popularity as a promising CRC therapeutic approach. Gao and colleagues demonstrated that treatment with (histidine decarboxylase) HDC⁺ L. reuteri can induce luminal histamine production, consequently, decreased colon tumor frequency and size were observed in HDC^-/- mice (Gao et al., 2017). Moreover, they discovered that an L. reuteri mutant with isogenic HDC deficiency that cannot generate histamine did not inhibit tumorigenesis, highlighting the essential function of histamine in preventing inflammatory responses and the development of colorectal tumors (Gao et al., 2017). Reuterin, another major compound produced by L. reuteri, was found to be downregulated in mice and human CRC (Bell et al., 2022). Consistently, reuterin has been shown to have an inhibitory impact on the proliferative rate of CRC cell lines such as RKO at a concentration of 25µM, but not at a higher dosage of 100µM on normal colonic epithelium (Yu et al., 2023b). Indole-3-lactic acid, a tryptophan catabolite that inhibits the IL-17 signaling pathway, was shown in another recent study to be a key player in the suppression of colorectal carcinogenesis following L. reuteri treatment (Han et al., 2023). RAR-related orphan receptor γt, a nuclear receptor, was the target of this microbial metabolite product, which prevented Th17 cell development (Han et al., 2023). The potential underlying mechanism of L. reuteri’s pro-apoptotic actions was investigated but still needs further investigation. L. reuteri MG5346 was reported to inhibit tumor growth by inducing cell apoptosis though upregulated caspase-9 activity (Kim et al., 2022b). Additionally, it has been demonstrated that sirtuin-3–L. reuteri interaction is essential for the development of gut tumors (Zhang et al., 2018). Sirtuin-3 is a tumor-suppressing gene and L. reuteri can inhibit the downregulation of Sirt3 expression during colorectal tumorigenesis (Zhang et al., 2018). A previous meta-analysis analyzed the relationship between intestine E-cadherin and the prognosis of CRC, they concluded that low expression of E-cadherin is a risk factor for poor prognosis in CRC sufferers (Chang et al., 2022). It has been evidenced that L. reuteri can boost E-cadherin expression, indicating a possible mechanism for treating CRC (Karimi et al., 2018).

In summary, considering these evidence, L. reuteri owns the ability to suppress intestinal tumor progression in direct and indirect ways, thereby it may develop into a potential adjuvant treatment, but it is premature to recommend widespread use of L. reuteri in CRC due to insufficient clinical data.

The total cirrhosis incidence is growing and estimated to reach 112.1/100,000 person-years in 2040, largely attributed to the increase in non-alcoholic fatty liver disease and alcohol-related liver disease (Flemming et al., 2021). The liver is a central immunological organ, which is frequently exposed to metabolites derived from the intestinal microbiome, thus it is not surprising that the GI microbial community also plays a part in the pathologic process of liver diseases (Jones and Neish, 2021; Wang et al., 2021a). Particularly, gut microbiota dysbiosis may already exist at the early period of liver damage. Studies have shown alcohol-dependent subjects with liver disorder show compositional changes in the fecal microbiota, presented as a reduction in bacterial diversity and decreased relative abundance of Lactobacillus, Bifidobacterium, as well as Akkermansia muciniphila (Leclercq et al., 2014; Grander et al., 2018). The phenotype of ethanol-elicited hepatitis was reversed by L. reuteri, partially by regulating fatty acid metabolic pathways in mice alcoholic liver disease models (Zheng et al., 2020). It was also reported that L. reuteri MJM60668 supplementation to mice fed a high-fat diet ameliorated hepatic steatosis by inhibiting lipogenesis, which may be attributed to the improvement of the gut microbiome dysbiosis (Werlinger et al., 2022). Chen and colleagues reported that gut microbiota imbalance promoted liver tumorigenesis and administration with L. reuteri can improve tryptophan metabolism and reduce hepatic sterol regulatory element-binding protein 2 expression, thus suppressing tumorigenesis (Chen et al., 2022). L. reuteri was also reported to reduce IL-17A secretion of group 3 innate lymphoid cells (ILC3s) in liver by upregulating acetate levels, thus exerting anti-tumor effects in mice with hepatocellular carcinoma (Hu et al., 2023). These evidences revealed the interaction between gut microbiome and hepatic immune response as well as metabolite signal pathways. Hence the use of L. reuteri in managing liver disorders has drawn a lot of attention from researchers, although RCT studies on the bacteria’s protective effects for patients with hepatic ailments are still inadequate. In one RCT research, Ferolla et al. discovered that a 3-months supplementation of L. reuteri with guar gum as well as inulin reduced hepatic steatosis in subjects with nonalcoholic steatohepatitis (Ferolla et al., 2016). However, another RCT study carried out in 2017 showed that in obese patients with type 2 diabetes, oral dosing of L. reuteri DSM 17938 for 12 weeks seemed to have no impact on the microbiota composition, adiposity, or liver steatosis, although, in some subjects with higher gut microbiota diversity before intervention, it increased insulin sensitivity (Mobini et al., 2017). The contrary outcomes may be attributed to the of microbial diversity in complicated metabolic disease conditions and the crosstalk caused by obesity. Taken together, these preclinical literatures provide evidence that L. reuteri may relieve liver injury in several signaling pathways probably by reversing gut microbiota dysbiosis. Given this, it may act as a potential probiotic for the prevention or therapeutic strategy for liver diseases, but further long-term well-designed clinical trials are still needed.

It is well-documented that L. reuteri can alter the bacterial diversity and abundance of various microorganisms, largely strain-specific. For instance, administration with L. reuteri LR6 and KT260178 both resulted in higher counts of total Lactobacillus, Bifidobacterium (Garg et al., 2020; Yang et al., 2020). While L. reuteri DSM 17938 supplement improved bacterial diversity along with enriched Firmicutes and reduced abundance of Bacteroidetes (Liu et al., 2019). Similar results have been observed in disease conditions. After supplement with L. reuteri DSM 17938, investigators observed enriched fecal Lactobacilli and a decrease in the colicky infants’ fecal E. coli counts (Savino et al., 2010; Savino et al., 2018b). Consistently, L. reuteri ATCC PTA 4659 peroral therapy alleviated mice colitis by maintaining the diversity of the colon’s microbiome (Liu et al., 2022a).

The beneficial properties of L. reuteri on gut microflora dysbiosis may be partially explained by the competition of L. reuteri and these harmful genera for the intestinal epithelium binding sites (Walsham et al., 2016). Walsham et al. reported that L. reuteri can bind to the epithelial cell surface by mucus-binding proteins CmbA and MUB, thus inhibiting enteropathogenic E. coli adherence to the gut epithelium (Walsham et al., 2016). Bioinformatics analysis further revealed that the inhibition mechanism may be associated with PI3K-Akt and MAPK signaling pathways (Qin et al., 2023b). Furthermore, L. reuteri may inhibit harmful bacteria by the production of antimicrobial metabolites like reuterin (Asare et al., 2020). The probiotic management of the gastrointestinal microbiota may also be mediated by regulating the intestinal pH through lactic acid production as well as some other antimicrobial substances like acetic acid and ethanol of some L. reuteri strains (Vitale et al., 2023). L. reuteri is demonstrated to be effective against a range of GI microbial infections, including Salmonella, Enterobacteriaceae, and others, partially depending on the synthesis of these compounds (Kao et al., 2020; Laosee et al., 2022; Qin et al., 2023a). In mice with colitis caused by dextran-sulfate-sodium, dosing of L. reuteri R2LC may remodel the makeup of the gut microbiome via enhanced intestinal IgA production (Liu et al., 2021a). It has been demonstrated that IgA is responsible for the selection of intestinal colonized bacteria and tends to resist pathogenic bacteria (Schnupf et al., 2018).

Overall, L. reuteri is shown to modulate the gut microbial community, characterized by enriched beneficial genera and diminished pathogenetic genera. Nonetheless, further research is required to determine the interaction between GI health and the modulated gut microbiota.

With the development of metabolomics and bacterial genetics strategy, small compounds produced by L. reuteri were identified. It has been proposed that the metabolite products of L. reuteri strains are responsible for their antibacterial and immunoregulatory properties. We covered a few well-known metabolites associated with L. reuteri’s probiotic potential in this section.

Numerous studies showed that intestinal epithelial barrier damage disrupts immune homeostasis and contributes to many intestinal disorders, especially IBD and CRC (Leibovitzh et al., 2023). The capacity of L. reuteri to boost gut barrier function has been demonstrated in several investigations (Yi et al., 2018; Gao et al., 2022). On one hand, L. reuteri owns the ability to maintain the intestinal epithelial repair function. Wu and colleagues found that L. reuteri reconstructed the epithelial integrity by activating the Wnt/β-catenin pathway, thereby promoting the intestine epithelial cell proliferation and inducing intestinal stem cell differentiation to Paneth cells, even under the condition of TNF-induced intestinal inflammation (Wu et al., 2020). On the other hand, L. reuteri was also reported to maintain the integrity of the gut barrier by upregulating the expression of TJ proteins, evidenced in in preclinical studies (Gao et al., 2022; Liu et al., 2022a; Li et al., 2023a). TJ proteins are primary for epithelial cell proliferation and gut permeability (Kuo et al., 2021). Bacterial extracellular membrane vesicles derived from L. reuteri contain lipoteichoic acid, identified as a Toll-like receptor (TLR) 2 activator (Pang et al., 2022). According to research, TLR2 activation strengthened the intestinal barrier by increased expression of TJ proteins via the PI3K-Akt-signaling pathway (Gu et al., 2016). L. reuteri was also reported to induce TJ proteins expression via the activated PKC-Nrf-2/HO-1pathway and inhibited NF-κB pathway, along with reduced apoptosis of intestinal epithelial cells (Zhou et al., 2022b). In conclusion, these results indicated the therapeutic benefits of L. reuteri in gastrointestinal diseases by repairing the gut barrier function though different pathways.

L. reuteri may exhibit beneficial effects in digestive system diseases via modulation of the immune system. DCs are crucial in the interaction between microorganisms and gut immune responses because of their advantageous location and capacity to present luminal antigens as “gatekeepers” (Saez et al., 2023). Mature DCs promote the polarization of naive T cells toward T helper (Th) 1, Th2, Th17, or Treg responses (Tiberio et al., 2018). L. reuteri 5454 treatment alleviated colitis inflammation in mice, the potential molecular mechanism might be explained by the efficiency of DCs primed with L. reuteri 5454 to promote Tregs differentiation and trigger IL-22 secretion (Hrdy et al., 2020). Another study revealed that L. reuteri 17938 may activate DCs via TLR2 and lead to Tregs expansion in the intestinal mucosa, thereby alleviating experimental necrotizing enterocolitis (Hoang et al., 2018). Further evidenced by in vitro experiments, L. reuteri cell-free supernatants promoted DCs differentiation with up-regulated surface markers (CCR7, CD83, CD86, HLA-DR) and enhanced cytokine synthesis (IL-6, IL-10, and IL-23), nonetheless, these DCs exhibited diminished phagocytic activity (Haileselassie et al., 2016). The similar results were also reported by Lasaviciute and his colleagues who showed that a mixed secondary response profile was produced in DCs after priming human monocytes with L. reuteri DSM17938 secretions, secreting low levels of TNF-α, and IL-27 and high levels of IL-1β and IL-6 (Lasaviciute et al., 2022). The particular manner by which L. reuteri modulates the phenotypic and operation of mucosal-like DC is yet fully understood. Notably, the involvement of surface proteins was examined recently in the interaction between L. reuteri and DCs. The study demonstrated that L. reuteri can promote the release of the immune-regulating IL-10 in monocyte-derived DCs independent of its mucus adhesins while the production of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) was enhanced by mucus adhesins (Bene et al., 2017).

Meanwhile, numerous preclinical studies showed L. reuteri also had the property to promote the proliferation of Tregs while suppressing the production of Th cells, specifically Th1 and Th2, accompanied by decreased mRNA expression of NF-κB, TLR4, TNF-α, IL-6, and upregulated IL-10 mRNA expression in the intestine (Hoang et al., 2018; Liu et al., 2019; Liu et al., 2023b). The forkhead box P3 (FoxP3) transcription factor is crucial in generating Tregs (Harada et al., 2022). And the FoxP3 mRNA expression level was shown to be elevated in peripheral blood after L. reuteri DSM 17938 administration in colicky infants (Savino et al., 2018b). In addition, the mechanism of Tregs induction may be associated with reprogrammed gut microbiota composition and SCFAs production by L. reuteri (Liu et al., 2019; Wen et al., 2021). However, the ability of L. reuteri to induce Tregs is generally strain-dependent, and certain L. reuteri strains have anti-inflammatory properties that are not always reliant on Tregs (Liu et al., 2021b; Liu et al., 2023a). Orally feeding L. reuteri can suppress Th1/Th2 responses in mesenteric lymph nodes in Treg-deficient mice via activation of adenosine A_2A receptors (Liu et al., 2023a). This phenomenon may be explained by the specific property of L. reuteri to increase the level of plasma adenosine metabolites such as inosine (Liu et al., 2021b). Proteomics studies using mass spectrometry confirmed that bacterial extracellular membrane vesicles derived from L. reuteri carried numerous bacterial cell surface proteins, including 5’-nucleotidase, which initiate the process by which AMP is transformed into the signal molecule adenosine (Pang et al., 2022).

Besides, L. reuteri seemed to be able to promote M2 macrophage polarization. Pro-inflammatory M1-like macrophage indicators may be suppressed by the stress protein GroEL isolated from L. reuteri, whereas M2-like markers are favored, consequently suppressing intestinal production of pro-inflammatory markers (TNF-α, IL-1β, interferon-γ) and increasing anti-inflammatory IL-10 and IL-13 by the activation of a TLR4 pathway (Dias et al., 2021). Except for these, Wang and colleagues reported that oral therapy of L. reuteri effectively inhibited the progression of mice colitis induced by immune checkpoint blockade treatment, and they highlighted that the therapeutic impact of L. reuteri ATCC PTA 6475 was related to a decrease of ILC3s (Wang et al., 2019). ILC3s are mainly found in the intestinal mucosa and can drive proinflammatory responses and cause immunopathological damage (Jarade et al., 2021). The mechanism is not fully clear. It is possible that L. reuteri’s capacity to metabolize tryptophan into indole derivatives, which subsequently activate the aryl hydrocarbon receptor in ILC3s, is responsible for the underlying mechanism (Zelante et al., 2013; Schiering et al., 2017). Furthermore, a previous study investigated two strains extracted from piglets, L. reuteri ZJ617 and L. reuteri ZJ615, characterized by high and low adhesive ability respectively (Gao et al., 2016). The study showed that L. reuteri ZJ615 reduced phosphorylation levels of ERK1/2 while L. reuteri ZJ617 had no significant effects on the ERK1/2 signaling pathway in the ilea of the LPS-stimulated mice model (Gao et al., 2016). Given this, L. reuteri’s capacity to modulate the immune system may be somewhat dependent on its adhesive property.

Overall, these studies demonstrated that metabolites and bacterial components of L. reuteri as well as the restored balance of the gut microbiota are both engaged in the suppression of excessive immune response and protection the intestine from injury.